RECRUITING

Solarplast (R) Supplementation Effects Following High-intensity Resistance Exercise

Conditions

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

The primary goal of this investigation is to assess whether Solarplast (R) supplementation will improve recovery following heavy resistance exercise in active adults. The primary questions to be addressed are: Does Solarplast (R) decrease muscle damage and inflammation associated with heavy resistance exercise? Does Solarplast (R) reduce the decline in performance associate with heavy resistance exercise? Researchers will compare Solarplast (R) to a placebo (a look-alike substance that contains no active ingredients) to see if Solarplast (R) is effective at improving recovery. Participants will be asked to: Take Solarplast (R) or placebo daily for 4 weeks Visit the laboratory at least once per week to receive their supplement Report to the lab for 3 consecutive visits following supplementation to complete a heavy resistance training session and follow-up testing.

Official Title

Effects of Solarplast (R) Supplementation on Biomarkers of Muscle Damage, Inflammation and Recovery of Physical Performance Following High-intensity Resistance Exercise

Quick Facts

Study Start:2024-04-17
Study Completion:2025-03-31
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT06432868

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years to 35 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:Yes
Standard Ages:ADULT
Inclusion CriteriaExclusion Criteria
  1. * Recreationally-active (participated in at least 2 weight training workouts per week over the previous year) and participates in at least 3h of total structured exercise/week as determined by the health and activity questionnaire.
  2. * Subject is judged by the Investigator to be healthy and free of any physical limitations (determined by health and activity questionnaire)
  3. * Subject has a body mass index of 18.0-34.9 kg/m2, inclusive
  4. * Subject is willing to maintain habitual diet throughout the study period
  5. * Subject is willing to abstain from dietary supplementation throughout the duration of the study.
  6. * Subject understands the study procedures and signs forms providing informed consent to participate in the study and authorization for release of relevant protected health information to the study Investigators
  1. * Subject is currently or will be enrolled in another clinical trial.
  2. * Subject is a habitual consumer of tea/antioxidants defined as \> 8 oz/day of either green or black tea within the 14 days prior to the screening visit.
  3. * Subject has a history or presence of a clinically relevant cardiac, renal, hepatic, endocrine (including diabetes mellitus), pulmonary, biliary, gastrointestinal, pancreatic, or neurologic disorder.
  4. * Subject has a history or presence of cancer in the prior 2 years, except for non-melanoma skin cancer.
  5. * Subject is unable to perform physical exercise (determined by health and activity questionnaire)
  6. * Subject is engaged in an extreme diet including but not limited to, Atkins, South Beach, Intermittent Fasting, etc.
  7. * Subject is allergic to the study product or placebo
  8. * Subject is taking any other nutritional supplement or performance enhancing drug (determined from health and activity questionnaire)
  9. * Subject has any chronic illness that causes continuous medical care
  10. * Taking any type of prescription or over-the-counter medication including but not limited to corticosteroids, non-steroidal anti-inflammatory drugs, and antibiotics within the 14 days prior to the screening visit.

Contacts and Locations

Study Contact

Adam R Jajtner, PhD
CONTACT
330-672-0212
ajajtner@kent.edu

Study Locations (Sites)

Kent State University - Exercise Science & Exercise Physiology
Kent, Ohio, 44242
United States

Collaborators and Investigators

Sponsor: Kent State University

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2024-04-17
Study Completion Date2025-03-31

Study Record Updates

Study Start Date2024-04-17
Study Completion Date2025-03-31

Terms related to this study

Additional Relevant MeSH Terms

  • Muscle Damage